290 related articles for article (PubMed ID: 26382043)
1. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs.
Duintjer Tebbens RJ; Pallansch MA; Thompson KM
BMC Infect Dis; 2015 Sep; 15():379. PubMed ID: 26382043
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy.
Duintjer Tebbens RJ; Thompson KM
Epidemiol Infect; 2017 Jan; 145(2):217-226. PubMed ID: 27760579
[TBL] [Abstract][Full Text] [Related]
3. Health Economic Analysis of Antiviral Drugs in the Global Polio Eradication Endgame.
Badizadegan K; Kalkowska DA; Thompson KM
Med Decis Making; 2023; 43(7-8):850-862. PubMed ID: 37577803
[TBL] [Abstract][Full Text] [Related]
4. Update on Immunodeficiency-Associated Vaccine-Derived Polioviruses - Worldwide, July 2018-December 2019.
Macklin G; Diop OM; Humayun A; Shahmahmoodi S; El-Sayed ZA; Triki H; Rey G; Avagyan T; Grabovac V; Jorba J; Farag N; Mach O
MMWR Morb Mortal Wkly Rep; 2020 Jul; 69(28):913-917. PubMed ID: 32673297
[TBL] [Abstract][Full Text] [Related]
5. New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data.
Shaghaghi M; Soleyman-Jahi S; Abolhassani H; Yazdani R; Azizi G; Rezaei N; Barbouche MR; McKinlay MA; Aghamohammadi A
Vaccine; 2018 Mar; 36(13):1711-1719. PubMed ID: 29478755
[TBL] [Abstract][Full Text] [Related]
6. An economic analysis of poliovirus risk management policy options for 2013-2052.
Duintjer Tebbens RJ; Pallansch MA; Cochi SL; Wassilak SG; Thompson KM
BMC Infect Dis; 2015 Sep; 15():389. PubMed ID: 26404632
[TBL] [Abstract][Full Text] [Related]
7. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.
Duintjer Tebbens RJ; Pallansch MA; Wassilak SG; Cochi SL; Thompson KM
BMC Infect Dis; 2016 Mar; 16():137. PubMed ID: 27009272
[TBL] [Abstract][Full Text] [Related]
8. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication.
Guo J; Bolivar-Wagers S; Srinivas N; Holubar M; Maldonado Y
Vaccine; 2015 Mar; 33(10):1235-42. PubMed ID: 25600519
[TBL] [Abstract][Full Text] [Related]
9. Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV).
Thompson KM; Kalkowska DA
Expert Rev Vaccines; 2019 Jul; 18(7):725-736. PubMed ID: 31248293
[No Abstract] [Full Text] [Related]
10. Poliovirus excretion following vaccination with live poliovirus vaccine in patients with primary immunodeficiency disorders: clinicians' perspectives in the endgame plan for polio eradication.
Galal NM; Meshaal S; ElHawary R; Nasr E; Bassiouni L; Ashghar H; Farag NH; Mach O; Burns C; Iber J; Chen Q; ElMarsafy A
BMC Res Notes; 2018 Oct; 11(1):717. PubMed ID: 30305145
[TBL] [Abstract][Full Text] [Related]
11. Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV.
Kalkowska DA; Thompson KM
Risk Anal; 2021 Feb; 41(2):312-319. PubMed ID: 32936466
[TBL] [Abstract][Full Text] [Related]
12. Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication.
Aghamohammadi A; Abolhassani H; Kutukculer N; Wassilak SG; Pallansch MA; Kluglein S; Quinn J; Sutter RW; Wang X; Sanal O; Latysheva T; Ikinciogullari A; Bernatowska E; Tuzankina IA; Costa-Carvalho BT; Franco JL; Somech R; Karakoc-Aydiner E; Singh S; Bezrodnik L; Espinosa-Rosales FJ; Shcherbina A; Lau YL; Nonoyama S; Modell F; Modell V; ; Barbouche MR; McKinlay MA
Front Immunol; 2017; 8():685. PubMed ID: 28952612
[TBL] [Abstract][Full Text] [Related]
13. A case for developing antiviral drugs against polio.
Collett MS; Neyts J; Modlin JF
Antiviral Res; 2008 Sep; 79(3):179-87. PubMed ID: 18513807
[TBL] [Abstract][Full Text] [Related]
14. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2016 May; 16():231. PubMed ID: 27230071
[TBL] [Abstract][Full Text] [Related]
15. Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters.
Kalkowska DA; Pallansch MA; Thompson KM
Epidemiol Infect; 2019 Oct; 147():e295. PubMed ID: 31647050
[TBL] [Abstract][Full Text] [Related]
16. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.
Thompson KM; Duintjer Tebbens RJ
BMC Infect Dis; 2015 Sep; 15():374. PubMed ID: 26381878
[TBL] [Abstract][Full Text] [Related]
17. Update on Vaccine-Derived Polioviruses - Worldwide, January 2016-June 2017.
Jorba J; Diop OM; Iber J; Henderson E; Sutter RW; Wassilak SGF; Burns CC
MMWR Morb Mortal Wkly Rep; 2017 Nov; 66(43):1185-1191. PubMed ID: 29095803
[TBL] [Abstract][Full Text] [Related]
18. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
Orenstein WA;
Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328
[TBL] [Abstract][Full Text] [Related]
19. Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2018 Apr; 18(1):165. PubMed ID: 29631539
[TBL] [Abstract][Full Text] [Related]
20. Neutralization capacity of highly divergent type 2 vaccine-derived polioviruses from immunodeficient patients.
McDonald SL; Weldon WC; Wei L; Chen Q; Shaw J; Zhao K; Jorba J; Kew OM; Pallansch MA; Burns CC; Steven Oberste M
Vaccine; 2020 Mar; 38(14):3042-3049. PubMed ID: 32089462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
